Back to the main directory
Company Analysis / Equity
- Morningstar | Synchrony's Higher Growth Offset by Lower Net Interest Margins by Morningstar
- FDA Cracks Down on Curaleaf’s CBD Marketing but No Long-Term Impact; Shares Remain Undervalued by Morningstar
- Morningstar | Snap Reports Impressive 2Q Results on All Fronts; Raising FVE to $15; Shares Fairly Valued by Morningstar
- ILIAD - BUY | EUR149 Sustained growth dynamic in Q1 by Bryan Garnier
- Morningstar | ASML on Track to Enjoy Steady Rise in Sales Over 2019 Thanks to EUV; Shares Overvalued by Morningstar
- Aptar Adds Capabilities to Its Competitively Advantaged Pharma Business; Raising FVE to $92 by Morningstar
- Morningstar | Rising Rates and Low Inflation Sting Santander Chile in 1Q; Interest Margin Hits a Multiyear Low by Morningstar
- Morningstar | Fee Pressure Trumps Positive Flows in BlackRock's 2Q; Keeping Our $495 FVE in Place by Morningstar
- Boston Beer Poised for Margin Improvement and Decelerating Volume Growth Over the Long Run by Morningstar
- Morningstar | Chevron Turns to the Permian for the Next Phase of Its Growth by Morningstar
- Coca-Cola Femsa's Pricing Strong in 1Q, but Macroeconomic Challenges Persist; Shares Undervalued by Morningstar
- EC Charges BMW, Daimler, and Volkswagen with Collusion on Emissions Technology; No FVE Changes by Morningstar
- Burdened With Excess Selling Space in a Changing Market, We Maintain Our View Macy’s Lacks a Moat by Morningstar
- Morningstar | After a Year of Consistent Revenue, Greenhill Has a Major Down Quarter by Morningstar
- Morningstar | HKMA Hands out Three Virtual Banking Licences in Competitive Hong Kong Banking Market by Morningstar
- Morningstar | Despite Recent Progress, IHS Markit Still Has Ample Room for Margin Growth by Morningstar
- Admission Struggles Stifle International Speedway’s Earnings Growth; Shares Overvalued by Morningstar
- Morningstar | Maintaining Our Lexicon FVE Following Zynquista's Europe Approval and Modest 1Q Xermelo Growth by Morningstar
- Morningstar | Road to Mattel's Turnaround Improving, but Fisher-Price Could Offer Near-Term Brand Equity Headwinds by Morningstar
- Morningstar | Posco’s 2Q Largely in Line With Expectations; FVE Cut to KRW 280,000 on Higher Raw Material Prices by Morningstar
- Morningstar | Eylea, Dupixent Solid in Regeneron's First Quarter; Maintaining Our Fair Value Estimate by Morningstar
- Morningstar | We Expect TIM Will struggle in Brazil as Converged Wireless and Fixed-line Networks Gain Importance by Morningstar
- Morningstar | Valero Hurt by Tough Macro Environment in 1Q, but Outlook Remains Favorable by Morningstar
- Morningstar | We're Maintaining Our Chipmaker FVEs, as We Don't Yet Foresee a Tech Cold War Despite the Huawei Ban by Morningstar
- Zimmer Biomet Makes Measured Progress in 1Q; No Change to Our FVE by Morningstar